Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation
Annals of Hematology · 2026
DOI: 10.1007/s00277-026-07221-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Cuicui Lyu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, No.2 Baoshan West Road, Xiqing District, Tianj…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Project of Tianjin Municipal Health Committee, Tianjin Key Medical Discipline Construction Project, Tianjin Key Clinical Specialty Construction Project.
Abstract (Originalsprache)
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the leading cause of treatment failure in high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), yet effective maintenance strategies are currently lacking. The combination of chidamide (CHI) and venetoclax (VEN) represents a novel approach. However, real-world data on its use are limited. In this study, eighteen high-risk transplant recipients received maintenance therapy with CHI (5 mg/day on days 1–7 or 1–14) plus VEN (100 mg on day 1, then 200 mg on days 2–7 or 2–14) every 2 months. Endpoints included overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and safety. After a median follow-up of 708 days, the 2-year OS and DFS were 73.9% and 56.6%, respectively. The 2-year CIR was 28.9%, and the 2-year NRM rate was 22.5%. The most common adverse events were hematologic, including neutropenia (13 episodes), thrombocytopenia (7), and anemia (7), all of which were manageable. No treatment-related mortality, tumor lysis syndrome, or severe acute graft-versus-host disease (GVHD) occurred. In conclusion, CHI plus VEN as post-transplant maintenance therapy shows encouraging efficacy and a manageable safety profile in high-risk AML/MDS patients, representing a promising strategy for relapse prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, No.2 Baoshan West Road, Xiqing District, Tianjin, 300192, China.
- Department of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, No.2 Baoshan West Road, Xiqing District, Tianjin, 300192, China. mingfengzhao@sina.com.
Förderung
- Science and Technology Project of Tianjin Municipal Health Committee
- Tianjin Key Medical Discipline Construction Project
- Tianjin Key Clinical Specialty Construction Project
Zitieren
APA
Lyu, C., Meng, H., Pu, Y., Luan, X., Lyu, H., Xiao, X., & Zhao, M. (2026). Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation. Annals of Hematology. https://doi.org/10.1007/s00277-026-07221-8
Vancouver
Lyu C, Meng H, Pu Y, Luan X, Lyu H, Xiao X, et al. Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation. Annals of Hematology. 2026. doi:10.1007/s00277-026-07221-8
BibTeX
@article{Lyu2026,
author = {Lyu, Cuicui and Meng, Haotian and Pu, Yedi and Luan, Xianshuang and Lyu, Hairong and Xiao, Xia and Zhao, Mingfeng},
title = {Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07221-8}
}
EUVIMED